

# BlueStar Genomic Health Care Index

The BlueStar Genomic Health Care Index provides exposure to globally listed companies developing or producing gene-based healthcare technologies and therapies.

## Key Features



**All Time High/Low**      **52-Week High/Low**

**Total Return Net Index**      381.50/69.17      381.50/200.22

### Size and Liquidity Requirements

Float-adjusted market capitalization of at least 300 mIn USD. Six-month average-daily-value-traded of at least 200000 USD.

### Universe

Companies developing or producing gene-based healthcare technologies and therapies.

### Diversification

Companies are liquidity weighted.

### Review

Semi-annual in June and December.

## Index Data

### INDEX PARAMETERS

<b>Launch Date</b>	22 May 2020	<b>Components</b>	82
<b>Type</b>	Sector	<b>Volatility</b> (1 year)	35.87
<b>Currency</b>	USD	<b>Full MCap</b> bn USD	722.89
<b>Base Date</b>	31 Dec 2015	<b>Float MCap</b> bn USD	441.97
<b>Base Value</b>	100.00	<b>Correlation*</b> (1 year)	0.60

\* MSCI ACWI Biotechnology

### FUNDAMENTALS\*

<b>Price/Earnings Trailing</b>	-17.52
<b>Price/Book</b>	4.64
<b>Price/Sales</b>	14.79
<b>Price/Cash Flow</b>	30.12
<b>Dividend Yield</b>	0.01

\* as of 31 Jul 2021



### ANNUALISED PERFORMANCE\*

<b>1 Month</b>	5.10%
<b>1 Year</b>	39.35%
<b>3 Years</b>	22.42%
<b>5 Years</b>	29.56%
<b>Since Inception</b>	21.76%

\* Total Return Net Index

## Country and Size Weightings

Country	Count	Weight
United States	63	78.56%
United Kingdom	4	4.34%
Germany	3	3.92%
France	2	2.26%
Japan	2	2.19%
China	2	2.03%
New Zealand	1	1.32%
Switzerland	1	1.26%
Canada	1	1.22%
Israel	1	1.05%
Netherlands	1	1.00%
Belgium	1	0.85%



Size	Count	Weight
Large-Cap (> 6 bn)	20	28.34%
Mid-Cap (1.5 bn - 6 bn)	29	37.69%
Small-Cap (0.2 bn - 1.5 bn)	33	33.97%
Micro-Cap (0.0 bn - 0.2 bn)	0	0.00%

## BlueStar Genomic Health Care Index

### Sector Weightings

Sector	Count	Weight
Health Care	82	100.00%



### Index Components

Top Components by Weight	Country	Weight	Best Performing Components	YTD	1 Day
Intellia Therapeutics, Inc.	US	2.46%	10X GENOMICS INC	22.70%	5.81%
Translate Bio, Inc.	US	2.32%	GUARDANT HEALTH INC	-2.08%	4.86%
MODERNA INC	US	2.17%	Gensight Biologics SA	11.11%	4.77%
Editas Medicine, Inc.	US	2.12%	Pacific Edge Ltd	11.69%	4.54%
ARCTURUS THERAPEUTICS HOLDINGS INC	US	2.00%	Rocket Pharmaceuticals, Inc	-38.64%	3.60%
BIONTECH SE	DE	1.83%			
Maravai LifeSciences Holdings-A	US	1.70%			
Veracyte Inc	US	1.64%			
ALNYLAM PHARMACEUTICALS INC	US	1.58%			
Anavex Life Sciences Corporation	US	1.56%			
Beam Therapeutics Inc.	US	1.53%			
REGENERON PHARMACEUTICALS	US	1.53%			
<b>Subtotal</b>		<b>22.44%</b>			

Worst Performing Components	YTD	1 Day
Design Therapeutics, Inc	-63.51%	-13.09%
ZIOPHARM Oncology Inc	-34.92%	-6.82%
Orchard Therapeutics PLC	-37.96%	-6.29%
Editas Medicine, Inc.	-11.85%	-5.69%
Generation Bio Co.	-14.71%	-5.55%

### Symbols

	Symbol	ISIN	WKN	Sedol	Bloomberg	Reuters	Telekurs
<b>Price Index</b>	-	-	-	-	-	-	-
<b>Total Return Net</b>	BDNANTR	DE000A3CLKA4	A3CLKA	BLNPNQ5	BDNANTR	.BDNANTR	57061641
<b>Total Return Gross</b>	-	-	-	-	-	-	-

For further information visit [www.mvis-indices.com](http://www.mvis-indices.com)

Nothing on this factsheet shall be considered a solicitation to buy or an offer to sell a security, or any other product or service, to any person in any jurisdiction where such offer, solicitation, purchase or sale would be unlawful under the laws of such jurisdiction. Neither MV Index Solutions GmbH nor any of its licensors makes any warranties or representations, express or implied, to the user with respect to any of the data contained herein. The data is provided for informational purposes only, and the Company shall not be responsible or liable for the accuracy, usefulness or availability of any information transmitted or made available through it. The MVIS® indices are protected through various intellectual property rights and unfair competition and misappropriation laws. In particular, Van Eck Associates Corporation has registered the "MVIS" trademark. You require a licence to launch any product whose performance is linked to the value of a particular MVIS® index and for all use of the MVIS® name or name of the MVIS® index in the marketing of the product. All information shown prior to the index launch date is simulated performance data created from backtesting ("simulated past performance"). Simulated past performance is not actual but hypothetical performance based on the same or fundamentally the same methodology that was in effect when the index was launched. Simulated past performance may materially differ from the actual performance. Actual or simulated past performance is no guarantee for future results.